Target Corporation (NYSE:TGT) shares are trading higher Friday following a Financial Times report indicating an activist investor has built a stake in the company.
What To Know: According to Bloomberg, citing the Financial Times, Toms Capital Investment Management has made a significant investment in Target, though specific details of the stake were not disclosed. The report cited people familiar with the matter who were not identified.
In response to a request for comment, Target said it maintains “regular dialogue with the investment community” and that its top priority is “getting back to growth.” The company said its plans to improve merchandise, the shopping experience and technology are intended to drive the business forward and deliver long-term value for shareholders.
A representative for Toms Capital Investment Management could not immediately be reached for comment by Bloomberg.
How To Buy Target Shares
By now you’re likely curious about how to participate in the market for Target – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.
If you’re looking to bet against a company, the process is more complex. You’ll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
See Also: What’s Going On With Coupang Shares Friday?
TGT Price Action: At the time of writing, Target shares are trading 2.15% higher at $98.62, according to data from Benzinga Pro.
Image via Shutterstock
Recent Comments